Predominant microvessel proliferation in coronary stent restenotic tissue in patients with diabetes: Insights from optical coherence tomography image analysis

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 843-847

  Suzuki, Nobuaki ^a   Kozuma, Ken ^a   Kyono, Hiroyuki ^a   Otsuki, Shuji ^a   Fu, Qiang ^a   Hosogoe, Naoyoshi ^a   Saito, Tomohisa ^a   Naito, Kazuya ^a   Ochiai, Mina ^a   Ishikawa, Shuichi ^a   Watanabe, Hidenori ^a   Miyazawa, Akiyoshi ^a   Eto, Kazuhiro ^a   Isshiki, Takaaki ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Coronary artery; Diabetes mellitus; Stent

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BARE METAL STENT; CAPILLARY PROLIFERATION; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY STENT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG ELUTING STENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN-STENT RESTENOSIS; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MICROVESSEL INDEX; MULTIVARIATE ANALYSIS; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

CORONARY ARTERY; DIABETES MELLITUS; STENT;

AGED; COHORT STUDIES; CORONARY RESTENOSIS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84885306618     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.002     Document Type: Article

References (42)

1. Costa MA, Angiolillo DJ, Tannenbaum M, et al. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol 2008;101: 1704-11.
2. Ikari Y, Kotani J, Kozuma K, Kyo E, Nakamura M, Yokoi H. Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS). Circ J 2009;73:1038-44.
3. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
4. Suzuki N, Nanda H, Angiolillo DJ, et al. Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. Int J Cardiovasc Imaging 2008;24:357-64.
5. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Vascular effects of sirolimuseluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006;47:2172-9.
6. Suzuki N, Costa MA. Intravascular ultrasound volumetric quantification: the current "gold standard" for characterization of coronary artery disease. Rev Esp Cardiol 2006;59:862-4.
7. Yamamoto M, Takano M, Murakami D, et al. Optical coherence tomography analysis for restenosis of drug-eluting stents. Int J Cardiol 2011;146:100-3.
8. Yamamoto M, Takano M, Murakami D, et al. Impact of small thrombus formation in restenotic bare-metal stent lesions associated with acute coronary syndrome: identification by optical coherence tomography. Int J Cardiol 2011;149:169-73.
9. Kim JS, Fan C, Choi D, et al. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol 2011;146:341-6.
10. Takano M, Murakami D, Yamamoto M, et al. Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: Comparison with paclitaxel-eluting stents. Int J Cardiol 2013;166:181-6.
11. Di Mario C, Barlis P. Optical coherence tomography: a new tool to detect tissue coverage in drug-eluting stents. JACC Cardiovasc Interv 2008;1:174-5.
12. Guagliumi G, Costa MA, Sirbu V, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONSAMI) Trial. Circulation 2011;123:274-81.
13. Suzuki N, Guagliumi G, Bezerra HG, et al. The impact of an eccentric intravascular ImageWire during coronary optical coherence tomography imaging. EuroIntervention 2011;6:963-9.
14. Suzuki N, Kozuma K, Maeno Y, et al. Quantitative coronary optical coherence tomography image analysis for the signal attenuation observed in-stent restenotic tissue. Int J Cardiol 2010;145:392-4.
15. Otake H, Shite J, Ikeno F, et al. Evaluation of the peri-strut low intensity area following sirolimus-and paclitaxel-eluting stents implantation: Insights from an optical coherence tomography study in humans. Int J Cardiol 2012;157:38-42.
16. Davlouros PA, Nikokiris G, Karantalis V, et al. Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study. Int J Cardiol 2011;151:155-9.
17. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115: 2426-34.
18. Imai M, Kadota K, Goto T, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation 2011;123:2382-91.
19. Kitabata H, Tanaka A, Kubo T, et al. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol 2010;105:1673-8.
20. Suzuki N, Kozuma K, Isshiki T. Role of Microvessels in Occlusive In-Stent Restenosis. Rev Esp Cardiol 2012;65:376.
21. Pels K, Labinaz M, O'Brien ER. Arterial wall neovascularization-potential role in atherosclerosis and restenosis. Jpn Circ J 1997;61:893-904.
22. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009;53:S35-42.
23. Akasaka T, Yoshida K, Hozumi T, et al. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol 1997;30:935-41.
24. Klein R, Klein BEK. Vision disorders in diabetes. In: 95-1468 NPN, editor. National Institutes of Health: National Institute of Diabetes and Digestive and Kidney Diseases 1995. p. 293.
25. Suzuki N, Coletta J, Guagliumi G, Costa MA. Clinical Applications of OCT. In: Lemos PA, editor. Diagnostic Methods In The Cardiac Catheterization Laboratory: A Practical Approach for Special Clinical Situations. London: Informa Healthcare; 2009.
26. Guagliumi G, Musumeci G, Sirbu V, et al. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2010;3:531-9.
27. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007;356:213-5.
28. Jimenez-Quevedo P, Suzuki N, Corros C, et al. Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis. Diabetes 2009;58:209-14.
29. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol 1999;188:189-96.
30. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-8.
31. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-61.
32. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
33. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67.
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: 837-53.
35. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004;21:657-65.
36. McCance DR, Ritchie CM, Kennedy L. Is HbA1 measurement superfluous in NIDDM? Diabetes Care 1988;11:512-4.
37. Nordquist L, Johansson M. Proinsulin C-peptide: friend or foe in the development of diabetes-associated complications? Vasc Health Risk Manag 2008;4:1283-8.
38. Tada T, Kimura T, Morimoto T, et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol 2011;107:1155-62.
39. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
40. CostaMA, Simon DI.Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73.
41. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation 2011;123:2954-63.
42. Habara M, Terashima M, Nasu K, et al. Difference of tissue characteristics between early and very late restenosis lesions after bare-metal stent implantation: an optical coherence tomography study. Circ Cardiovasc Interv 2011;4:232-8.